Board Change • Apr 08
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Joshua Gordon was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Feb 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 114% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 2.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (114% increase in shares outstanding). Market cap is less than US$10m (AU$5.91m market cap, or US$4.19m). Minor Risk Revenue is less than US$5m (AU$5.1m revenue, or US$3.6m). Announcement • Feb 09
Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 414,682,381
Price\Range: AUD 0.0046
Discount Per Security: AUD 0.000276
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 74,448,054
Price\Range: AUD 0.0046
Discount Per Security: AUD 0.000276
Transaction Features: Subsequent Direct Listing New Risk • Dec 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 2.9% per year over the past 5 years. Market cap is less than US$10m (AU$2.85m market cap, or US$1.91m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Revenue is less than US$5m (AU$5.1m revenue, or US$3.4m). Announcement • Dec 10
Anagenics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Anagenics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 414,682,381
Price\Range: AUD 0.0046
Discount Per Security: AUD 0.000276
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 74,448,054
Price\Range: AUD 0.0046
Discount Per Security: AUD 0.000276
Transaction Features: Subsequent Direct Listing Announcement • Oct 18
Anagenics Limited, Annual General Meeting, Nov 25, 2025 Anagenics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 2, 55 clarence street, sydney nsw 2000 Australia Reported Earnings • Aug 29
Full year 2025 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2024) Full year 2025 results: AU$0.003 loss per share (improved from AU$0.018 loss in FY 2024). Revenue: AU$5.12m (down 53% from FY 2024). Net loss: AU$1.24m (loss narrowed 83% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Board Change • Aug 06
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Executive Director Scott Greasley was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Executive Director Scott Greasley was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 21
Anagenics Limited, Annual General Meeting, Nov 26, 2024 Anagenics Limited, Annual General Meeting, Nov 26, 2024. Location: level 2, 55 clarence street sydney nsw 2000, sydney Australia Announcement • Oct 16
Matthew Perry, Sarah Jane Perry, and entities they control completed the acquisition of Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1). Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1) on October 2, 2024. The consideration comprises the assumption of Face Medigroup's liabilities and cancellation of the Anagenics Limited's obligation to pay approximately AUD 0.67 million by way of deferred consideration and loan repayment. No cash consideration will be exchanged on settlement of the transaction. The transaction is expected to close on October 15, 2024.
Matthew Perry, Sarah Jane Perry, and entities they control completed the acquisition of Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1) on October 16, 2024. Announcement • Oct 08
Anagenics Limited Announces Retirement of Karen Mathews as Chief Executive Officer Anagenics Limited announced that Karen Mathews who took on the role of CEO in March 2024 will retire from her role to enable the business to operate in a substantially reduced operating cost base reflecting the reduced size and complexity of the business. BLC Cosmetics Ltd. will be managed by existing management who have been operational in the business since 2023 reporting to the Board of Anagenics. Karen will continue to support Anagenics including advisory services if needed to assess future strategic opportunities. All Board members continue to provide their services on an unpaid basis. Announcement • Oct 03
Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1). Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited (ASX:AN1) on October 2, 2024. The consideration comprises the assumption of Face Medigroup's liabilities and cancellation of the Anagenics Limited's obligation to pay approximately AUD 0.67 million by way of deferred consideration and loan repayment. No cash consideration will be exchanged on settlement of the transaction. The transaction is expected to close on October 15, 2024. New Risk • Sep 07
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.8m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (AU$3.69m market cap, or US$2.46m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding). Announcement • Feb 07
Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.32068 million. Anagenics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.32068 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 40,355,000
Price\Range: AUD 0.016
Discount Per Security: AUD 0.0008
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,187,500
Price\Range: AUD 0.016
Discount Per Security: AUD 0.0008
Transaction Features: Subsequent Direct Listing Announcement • Oct 27
Anagenics Limited, Annual General Meeting, Nov 27, 2023 Anagenics Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: Level 5, 126 Phillip Street, Sydney Nsw 2000 New South Wales Australia Agenda: To consider adoption of Remuneration Report; to consider re-election of Mr Phillip Christopher as a Director; to consider Election of Ms Karen Matthews as a Director; and to consider other matters. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.017 loss in FY 2022) Full year 2023 results: AU$0.007 loss per share (improved from AU$0.017 loss in FY 2022). Revenue: AU$9.11m (down 1.3% from FY 2022). Net loss: AU$1.74m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Announcement • Aug 22
Anagenics Limited (ASX:AN1) agreed to acquire Face MediGroup for AUD 1.3 million. Anagenics Limited (ASX:AN1) agreed to acquire Face MediGroup for AUD 1.3 million on August 22, 2023. As part of the agreement, Anagenics will pay (I) deferred cash consideration of AUD 500,000, payable in 3 tranches; Tranche 1 – AUD 100,000 payable on completion, Tranche 2 – AUD 100,000 payable December 31, 2023, Tranche 3 – AUD 300,000 payable March 31, 2024, (II) AUD 250,000 AN1 scrip issued at the 30 days VWAP prior to completion and (III) adoption of shareholder and supplier loans owed by Face Medigroup amounting to approximately AUD 350,000. As part of the total purchase, AN1 will forgive a AUD 150,000 loan owed by FMG. As part of the agreement, deferred consideration of AUD 300,000 cash payable post FY24 subject to BLC Cosmetics (consolidating FMG and founder salaries) achieving FY24 EBITDA of at least AUD 1 million and AUD 300,000 cash payable post FY25 subject to BLC Cosmetics (consolidating FMG and founder salaries) achieving FY25 EBITDA of at least AUD 2.2 million. All cash consideration is intended to be funded by AN1 balance sheet. As of December 31, 2022, Face MediGroup reported revenue of AUD 0.004 million, Net loss of AUD 122 and EBITDA of -117. Face Medigroup co-founders, Matt and Sarah Perry, will officially join AN1 to lead the new integrated beauty business and will be aligned through AN1 scrip participation. The acquisition will be completed 5 days after satisfaction of the condition’s precedent, which is anticipated to be around September 29, 2023. New Risk • Aug 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (AU$6.58m market cap, or US$4.25m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Announcement • Feb 15
Anagenics Limited Appoints Karen Matthews as Non-Executive Director Anagenics Limited announced that, subject to finalisation of customary onboarding requirements, Karen Matthews will be joining the Board as a Non-Executive Director. Karen is a business transformation advisor with over 25 years' experience leading business turnaround, change and strategies for business growth. Karen brings dynamic experience from the Beauty & Retail industry working for some of Australia's most iconic retail businesses including Ella Bache, Freedom Furniture and Myer and being recognised with industry awards. Reported Earnings • Feb 14
First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.009 loss in 1H 2022) First half 2023 results: AU$0.002 loss per share (improved from AU$0.009 loss in 1H 2022). Revenue: AU$5.15m (up 23% from 1H 2022). Net loss: AU$533.0k (loss narrowed 70% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Announcement • Nov 29
Anagenics Approves the Election of Mr. Alexander Beard as A Director Anagenics Limited at the AGM held on November 29, 2022 approved the election of Mr. Alexander Beard as a Director. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Executive Director Scott Greasley was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 28
Anagenics Limited, Annual General Meeting, Nov 29, 2022 Anagenics Limited, Annual General Meeting, Nov 29, 2022, at 09:00 AUS Eastern Standard Time. Location: Level 5, 126Phillip Street, Sydney NSW 2000. Sydney Nsw 2000 Australia Agenda: To receive and to consider the Annual Financial Report of the Company for the financial year ended 30 June 2022; To Adopt Remuneration Report; To Approve Issue of Director Fee Shares to Dennis Eck; To approve Issue of Performance Rights to Scott Greasley, a Director of the Company; To approve Listing Rule 7.1A Approval of Future Issue of Securities; and to consider amendment to Constitution. Announcement • Oct 17
Anagenics Limited Announces Resignation of Dennis Eck as Director The Board of Anagenics Limited announced the intention of Mr. Dennis Eck to retire as a director following the completion of the Company's 2022 Annual General Meeting. Mr. Eck made a strategic investment in the company in December 2017 and has been a Non- Executive Director at Anagenics since March 2018. Dennis has been supportive of the continuing restructuring and repositioning of the Business and expresses his intention to continue as a supportive shareholder. Reported Earnings • Aug 26
Full year 2022 earnings released: AU$0.017 loss per share (vs AU$0.027 loss in FY 2021) Full year 2022 results: AU$0.017 loss per share (up from AU$0.027 loss in FY 2021). Revenue: AU$9.23m (up 59% from FY 2021). Net loss: AU$3.65m (loss narrowed 4.1% from FY 2021). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Announcement • Jul 09
Anagenics Limited Appoints Scott Mitchell Greasley as Director Anagenics Limited announced appointment of Scott Mitchell Greasley as director of the company. Date of appointment is on 8 July 2022. Announcement • Mar 01
Anagenics Limited Appoints Matthew Dudek as Acting Chief Executive Officer, Effective 28 February 2022 Anagenics Limited advised that it has appointed Matthew Dudek as Acting Chief Executive Officer, effective 28 February 2022. Maria Halasz has resigned as CEO and Managing Director of Anagenics Limited, effective on the same date. Matthew has been the Company's Group Financial Controller since the beginning of 2020. He is a member of Chartered Accountants Australia and New Zealand. Since joining Anagenics Matthew has played a key role in the day-to-day management of the Company, has a deep knowledge of the business and a strong track record in implementing profit improvementinitiatives and strategies. Reported Earnings • Feb 17
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.009 loss per share (up from AU$0.018 loss in 1H 2021). Revenue: AU$4.18m (up 50% from 1H 2021). Net loss: AU$1.75m (loss narrowed 23% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 130%, compared to a 20% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 25
Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.045 loss in FY 2020) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2021 results: Revenue: AU$5.82m (down 21% from FY 2020). Net loss: AU$3.80m (loss narrowed 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 22
Full year 2021 earnings released: AU$0.027 loss per share (vs AU$0.05 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$5.82m (down 22% from FY 2020). Net loss: AU$3.80m (loss narrowed 23% from FY 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Announcement • Apr 29
An unknown buyer signed a binding agreement to acquired Lyramid Limited from Cellmid Limited (ASX:CDY) for AUD 0.5 million An unknown buyer signed a binding agreement to acquired Lyramid Limited from Cellmid Limited (ASX:CDY) for AUD 0.5 million on April 29, 2021. In addition to the immediate cash payment of AUD 0.5 million the divestment of Lyramid will deliver a number of tangible benefits to Cellmid shareholders. Reported Earnings • Feb 19
First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.016 loss in 1H 2020) The company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: AU$2.79m (down 24% from 1H 2020). Net loss: AU$2.39m (loss widened 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Announcement • Feb 10
Cellmid Limited Publishes Data on Novel Proprietary FGF5 Aptamer Cellmid Limited to advise that results of its research and development program into high performing FGF5 aptamers have been published in Scientific Reports, part of the Nature publishing group1. The company, via its Advangen Inc. subsidiary, has been researching novel FGF5 inhibitors, including highly specific aptamers since its acquisition in 2013. The FGF5 aptamer research is conducted in collaboration with the University of Hokkaido, Yokohama National University and the Chiba Institute of Technology. Most recent results have shown that the newly identified aptamer constructs inhibiting FGF5 are highly effective and specific, as shown in FGF5 responsive cell lines. These findings have been published in Scientific Reports and are subject to a patent application filed by Advangen Inc., Cellmid's Japanese subsidiary. The patent application was published on 14 January 2021 and covers their composition as pharmaceutical FGF5 inhibitors for use against hair loss. FGF5 is a critical regulator of hair growth, initiating the transition of hair follicles out of growth and into rest and fall. The company, via its Advangen subsidiaries, markets a number of botanically based FGF5 inhibiting hair growth products under the évolis®, Jo-Ju® and Lexilis® brands. Performance of the Company's FGF5 inhibitor technology and brands has previously been demonstrated via two published clinical studies, showing their efficacy against hair loss, and in promoting hair growth. The company also holds a number of patents around key FGF5 inhibiting monoterpene molecules of plant origin. The latest research demonstrates a significant technological advance into synthetic molecules with high specificity and affinity to the FGF5 protein. The research program targets the development of novel FGF5 binding RNA aptamers using a SELEX enrichment approach2. The aptamers were optimised for high affinity (Kd 0.118 0.7 nM) of binding to FGF5, and high specificity, showing no binding activity with closely related FGF family members or the FGFR1 receptor. The aptamers were subsequently demonstrated to have biological FGF5 inhibitory activity via assays against an FGF5 responsive cell line. The FGF5 inhibitor aptamers add to the Company's proprietary antiaging hair care technologies and underpin Cellmid's scientific leadership in the field. As part of company's new product development program, further characterization of these novel FGF5 aptamers continues in Advangen's Tokyo Laboratories, via in-vitro and ex-vivo experimentation, alongside other programs ultimately directed to the development of novel formulations for hair loss in humans. Announcement • Jan 26
Cellmid Limited Receives the First Order from Ourui Health Management Limited Cellmid Limited announced that it has received the first order from Ourui Health Management Limited (OHM) pursuant to the distribution agreement signed on 14 December 2020 for the sale of Jo-Ju® and Lexilis® products in China (ASX announcement 14 December 2020). The first order has been received for 66,000 bottles of Jo-Ju® shampoo to be delivered in bulk, as no import permit has been received for the fully finished shampoo yet. These will be packaged in China at OHM's costs. An order has also been placed for 18,672 bottles of fully finished Jo-Ju® lotions with import permit. The order will be delivered in February and April 2021 and has a combined revenue of $530K which is paid before and will accrue on delivery. This is the first order, and part of the 500,000 unit order requirement for the first twelve months of the contract. It is anticipated that approximately half of the first-year orders will be received in October 2021, in preparation for the largest shopping day in the Chinese retail calendar (Singles day, 11/11). Minimum purchase orders increase to 1,000,000 units in year two and double digit (percentage) annual increases thereafter. Announcement • Dec 25
Cellmid Limited Announces Executive Changes Cellmid Limited that independent chairman, Dr. David King, will leave the Board on 31 December 2020. The temporary extension of Dr. King's tenure assisted in an orderly transition and the new independent chairman, Mr. Bruce Gordon, will take over from 1 January 2021. Mr. Gordon will also chair the Company's Nomination and Remuneration Committee from 1 January 2020, while relinquishing his role as Chair of the Audit Committee to Dr. Martin Cross. Announcement • Dec 15
Cellmid Limited, Advangen Limited and Advangen Inc. Signs 10 Year Chinese Distribution Agreement with Ourui Health Management Limited Cellmid Limited announced that it has signed, via its subsidiaries Advangen Limited and Advangen Inc. (Japan), an exclusive master distribution agreement (Agreement) with Ourui Health Management Limited (Distributor) for the distribution of its Japanese, Ju-Ju® and Lexilis® branded, anti-aging hair and skincare products (Products). Key terms of the Agreement are: Ten-year agreement: It is for a period of ten years, extendable by ten additional years, subject to performance by the Distributor and is exclusive for Asia (including all countries except Japan); Distributor to invest in marketing: The Distributor will bear the costs of marketing, brand building, social media, live streaming, celebrity endorsements and traffic campaigns; Minimum purchase orders: The Distributor must order the Minimum Annual Purchase Requirement of 500,000 units of products collectively across the two brands in year 1 and 1,000,000 units of products in Year 2, with double digit (percentage) annual purchase increases thereafter; Effect on fiscal 2021 revenue: Shipment of products under the Agreement is expected to commence during the second half of fiscal 2021; Termination: The Agreement may be terminated by either party in the event of a breach. From year 2 onwards, not meeting the Minimum Annual Purchase Requirement by the Distributor is a breach of the Agreement. Either party may also terminate the Agreement if there is a change in ownership or control of the counterparty. Announcement • Dec 03
Cellmid Limited Appoints Sarah Eck-Thompson as Director Cellmid Limited announced appointment of Sarah Eck-Thompson as director of the company. Date of appointment is 30 November 2020. 
